{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:40:43Z","timestamp":1793749243051,"version":"4.6.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005089","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7222270"],"award-info":[{"award-number":["7222270"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12012-025-09979-1","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T09:35:15Z","timestamp":1741340115000},"page":"805-819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Cardiotoxicity Risk of Immune Checkpoint Inhibitors Compared with Chemotherapy: A Systematic Review and Meta-analysis of Observational Studies"],"prefix":"10.1007","volume":"25","author":[{"given":"Yingying","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zishen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"9979_CR1","unstructured":"Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology (CSCO). (2023). Cardio-onclolgy guideline. (2023). Beijing, China. People's Medical Publishing House. 2023."},{"issue":"9","key":"9979_CR2","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","volume":"64","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa, P., & Yeh, E. T. (2014). Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities. Journal of the American College of Cardiology, 64(9), 938\u2013945.","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"9979_CR3","first-page":"570","volume":"72","author":"BE Gould Rothberg","year":"2022","unstructured":"Gould Rothberg, B. E., Quest, T. E., Yeung, S. J., et al. (2022). Oncologic emergencies and urgencies: A comprehensive review. CA: A Cancer Journal for Clinicians, 72(6), 570\u2013593.","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"11","key":"9979_CR4","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","volume":"6","author":"LH Lehmann","year":"2021","unstructured":"Lehmann, L. H., Cautela, J., Palaskas, N., et al. (2021). Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: A narrative review. JAMA Cardiology, 6(11), 1329\u20131337.","journal-title":"JAMA Cardiology"},{"issue":"5","key":"9979_CR5","doi-asserted-by":"publisher","first-page":"e145186","DOI":"10.1172\/JCI145186","volume":"131","author":"J Moslehi","year":"2021","unstructured":"Moslehi, J., Lichtman, A. H., Sharpe, A. H., et al. (2021). Immune checkpoint inhibitor-associated myocarditis: Manifestations and mechanisms. The Journal of clinical investigation, 131(5), e145186.","journal-title":"The Journal of clinical investigation"},{"issue":"12","key":"9979_CR6","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo, J., Page, D. B., Li, B. T., et al. (2015). Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 26(12), 2375\u20132391.","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"key":"9979_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.962596","volume":"13","author":"L Gan","year":"2022","unstructured":"Gan, L., Liu, D., Ma, Y., et al. (2022). Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges. Frontiers in Pharmacology, 13, 962596.","journal-title":"Frontiers in Pharmacology"},{"issue":"12","key":"9979_CR8","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1182\/blood.2020007878","volume":"137","author":"F Moik","year":"2021","unstructured":"Moik, F., Chan, W. E., Wiedemann, S., et al. (2021). Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood, 137(12), 1669\u20131678.","journal-title":"Blood"},{"issue":"12","key":"9979_CR9","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem, J. E., Manouchehri, A., Moey, M., et al. (2018). Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. The Lancet Oncology, 19(12), 1579\u20131589.","journal-title":"The Lancet Oncology"},{"key":"9979_CR10","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis, P., Jochum, F., Abbar, B., et al. (2024). Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective. EClinicalMedicine, 70, 102536.","journal-title":"EClinicalMedicine"},{"key":"9979_CR11","doi-asserted-by":"publisher","first-page":"1255825","DOI":"10.3389\/fimmu.2024.1255825","volume":"15","author":"C Zhang","year":"2024","unstructured":"Zhang, C., Wei, F., Ma, W., et al. (2024). Immune-related cardiovascular toxicities of PD-1\/PD-L1 inhibitors in solid tumors: An updated systematic review and meta-analysis. Frontiers in Immunology, 15, 1255825.","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"9979_CR12","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1161\/HYPERTENSIONAHA.122.19865","volume":"79","author":"S Minegishi","year":"2022","unstructured":"Minegishi, S., Kinguchi, S., Horita, N., et al. (2022). Immune checkpoint inhibitors do not increase short-term risk of hypertension in cancer patients: A systematic literature review and meta-analysis. Hypertension, 79(11), 2611\u20132621.","journal-title":"Hypertension"},{"key":"9979_CR13","doi-asserted-by":"publisher","first-page":"908173","DOI":"10.3389\/fimmu.2022.908173","volume":"13","author":"S Liu","year":"2022","unstructured":"Liu, S., Gao, W., Ning, Y., et al. (2022). Cardiovascular toxicity with PD-1\/PD-L1 inhibitors in cancer patients: A systematic review and meta-analysis. Frontiers in Immunology, 13, 908173.","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"9979_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/cpt.946","volume":"103","author":"RA Miksad","year":"2018","unstructured":"Miksad, R. A., & Abernethy, A. P. (2018). Harnessing the power of real-world evidence (RWE): A checklist to ensure regulatory-grade data quality. Clinical Pharmacology and Therapeutics, 103(2), 202\u2013205.","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"6","key":"9979_CR15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jhep.2024.01.018","volume":"80","author":"G Cabibbo","year":"2024","unstructured":"Cabibbo, G., Celsa, C., Rimassa, L., et al. (2024). Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice. Journal of Hepatology, 80(6), 957\u2013966.","journal-title":"Journal of Hepatology"},{"key":"9979_CR16","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati, A., Altman, D. G., Tetzlaff, J., et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ (Clinical Research Ed), 339, b2700.","journal-title":"BMJ (Clinical Research Ed)"},{"issue":"1","key":"9979_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","volume":"7","author":"AA Veroniki","year":"2016","unstructured":"Veroniki, A. A., Jackson, D., Viechtbauer, W., et al. (2016). Methods to estimate the between-study variance and its uncertainty in meta-analysis. Research Synthesis Methods, 7(1), 55\u201379.","journal-title":"Research Synthesis Methods"},{"issue":"1","key":"9979_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamadermatol.2023.4090","volume":"160","author":"JP Ingrassia","year":"2024","unstructured":"Ingrassia, J. P., Maqsood, M. H., Gelfand, J. M., et al. (2024). Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: A systematic review and meta-analysis. JAMA Dermatology, 160(1), 28\u201336.","journal-title":"JAMA Dermatology"},{"issue":"4","key":"9979_CR19","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg, C. B., & Mazumdar, M. (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50(4), 1088\u20131101.","journal-title":"Biometrics"},{"issue":"7109","key":"9979_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., Davey Smith, G., Schneider, M., et al. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed), 315(7109), 629\u2013634.","journal-title":"BMJ (Clinical Research Ed)"},{"issue":"3","key":"9979_CR21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin, L., & Chu, H. (2018). Quantifying publication bias in meta-analysis. Biometrics, 74(3), 785\u2013794.","journal-title":"Biometrics"},{"issue":"18","key":"9979_CR22","doi-asserted-by":"publisher","first-page":"18531","DOI":"10.1002\/cam4.6455","volume":"12","author":"J Zhu","year":"2023","unstructured":"Zhu, J., Chen, Y., Zhang, Y., et al. (2023). Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study. Cancer Medicine, 12(18), 18531\u201318541.","journal-title":"Cancer Medicine"},{"issue":"1","key":"9979_CR23","doi-asserted-by":"publisher","first-page":"e006072","DOI":"10.1136\/jitc-2022-006072","volume":"11","author":"AA Khorana","year":"2023","unstructured":"Khorana, A. A., Palaia, J., Rosenblatt, L., et al. (2023). Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer. Journal for Immunotherapy of Cancer, 11(1), e006072.","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"8","key":"9979_CR24","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/ajh.26954","volume":"98","author":"A Li","year":"2023","unstructured":"Li, A., May, S. B., La, J., et al. (2023). Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy. American Journal of Hematology, 98(8), 1214\u20131222.","journal-title":"American Journal of Hematology"},{"issue":"11","key":"9979_CR25","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1007\/s00262-023-03508-1","volume":"72","author":"C Iwai","year":"2023","unstructured":"Iwai, C., Jo, T., Konishi, T., et al. (2023). Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: A nationwide inpatient database study. Cancer Immunology, Immunotherapy: CII, 72(11), 3581\u20133591.","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"issue":"9","key":"9979_CR26","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.3390\/cancers14092320","volume":"14","author":"SH Lee","year":"2022","unstructured":"Lee, S. H., Cho, I., You, S. C., et al. (2022). Cancer therapy-related cardiac dysfunction in patients treated with a combination of an immune checkpoint inhibitor and doxorubicin. Cancers, 14(9), 2320.","journal-title":"Cancers"},{"issue":"5","key":"9979_CR27","doi-asserted-by":"publisher","first-page":"100252","DOI":"10.1016\/j.esmoop.2021.100252","volume":"6","author":"P Jain","year":"2021","unstructured":"Jain, P., Gutierrez Bugarin, J., Guha, A., et al. (2021). Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. ESMO Open, 6(5), 100252.","journal-title":"ESMO Open"},{"issue":"6","key":"9979_CR28","doi-asserted-by":"publisher","first-page":"e002771","DOI":"10.1136\/jitc-2021-002771","volume":"9","author":"J Gong","year":"2021","unstructured":"Gong, J., Drobni, Z. D., Zafar, A., et al. (2021). Pericardial disease in patients treated with immune checkpoint inhibitors. Journal for Immunotherapy of Cancer, 9(6), e002771.","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"5","key":"9979_CR29","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/jth.15272","volume":"19","author":"O Icht","year":"2021","unstructured":"Icht, O., Darzi, N., Shimony, S., et al. (2021). Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. Journal of Thrombosis and Haemostasis, 19(5), 1250\u20131258.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"9979_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.thromres.2021.10.014","volume":"208","author":"H Hill","year":"2021","unstructured":"Hill, H., Robinson, M., Lu, L., et al. (2021). Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy. Thrombosis Research, 208, 71\u201378.","journal-title":"Thrombosis Research"},{"key":"9979_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.lungcan.2020.10.017","volume":"150","author":"R Bishnoi","year":"2020","unstructured":"Bishnoi, R., Shah, C., Blaes, A., et al. (2020). Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study: CVD outcomes with the use of ICI in mNSCLC. Lung Cancer (Amsterdam, Netherlands), 150, 172\u2013177.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"24","key":"9979_CR32","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni, Z. D., Alvi, R. M., Taron, J., et al. (2020). Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation, 142(24), 2299\u20132311.","journal-title":"Circulation"},{"issue":"7","key":"9979_CR33","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1007\/s12325-020-01386-y","volume":"37","author":"ML Canale","year":"2020","unstructured":"Canale, M. L., Camerini, A., Casolo, G., et al. (2020). Incidence of pericardial effusion in patients with advanced non-small cell lung cancer receiving immunotherapy. Advances in Therapy, 37(7), 3178\u20133184.","journal-title":"Advances in Therapy"},{"issue":"2","key":"9979_CR34","first-page":"182","volume":"1","author":"KR Chitturi","year":"2019","unstructured":"Chitturi, K. R., Xu, J., Araujo-Gutierrez, R., et al. (2019). Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer. JACC: CardioOncology, 1(2), 182\u2013192.","journal-title":"JACC: CardioOncology"},{"issue":"29","key":"9979_CR35","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.21.01808","volume":"40","author":"D Laenens","year":"2022","unstructured":"Laenens, D., Yu, Y., Santens, B., et al. (2022). Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. Journal of Clinical Oncology, 40(29), 3430\u20133438.","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"9979_CR36","first-page":"6074","volume":"11","author":"C Zhang","year":"2021","unstructured":"Zhang, C., Chen, Z., Mo, C., et al. (2021). Real-world cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A retrospective controlled cohort study. American Journal of Cancer Research, 11(12), 6074\u20136085.","journal-title":"American Journal of Cancer Research"},{"issue":"2","key":"9979_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval, S., & Tweedie, R. (2000). Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics, 56(2), 455\u2013463.","journal-title":"Biometrics"},{"issue":"12","key":"9979_CR38","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nri3108","volume":"11","author":"LS Walker","year":"2011","unstructured":"Walker, L. S., & Sansom, D. M. (2011). The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nature Reviews Immunology, 11(12), 852\u2013863.","journal-title":"Nature Reviews Immunology"},{"issue":"21","key":"9979_CR39","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","volume":"25","author":"RV Parry","year":"2005","unstructured":"Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., et al. (2005). CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Molecular and Cellular Biology, 25(21), 9543\u20139553.","journal-title":"Molecular and Cellular Biology"},{"issue":"21","key":"9979_CR40","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1161\/CIRCULATIONAHA.117.029626","volume":"136","author":"G Varricchi","year":"2017","unstructured":"Varricchi, G., Galdiero, M. R., & Tocchetti, C. G. (2017). Cardiac toxicity of immune checkpoint inhibitors: Cardio-oncology meets immunology. Circulation, 136(21), 1989\u20131992.","journal-title":"Circulation"},{"issue":"7","key":"9979_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11912-020-00925-8","volume":"22","author":"A Khunger","year":"2020","unstructured":"Khunger, A., Battel, L., Wadhawan, A., et al. (2020). New insights into mechanisms of immune checkpoint inhibitor-induced cardiovascular toxicity. Current Oncology Reports, 22(7), 65.","journal-title":"Current Oncology Reports"},{"issue":"6","key":"9979_CR42","doi-asserted-by":"publisher","first-page":"111611","DOI":"10.1016\/j.celrep.2022.111611","volume":"41","author":"T Won","year":"2022","unstructured":"Won, T., Kalinoski, H. M., Wood, M. K., et al. (2022). Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Reports, 41(6), 111611.","journal-title":"Cell Reports"},{"issue":"7937","key":"9979_CR43","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod, M. L., Meijers, W. C., Screever, E. M., et al. (2022). T cells specific for alpha-myosin drive immunotherapy-related myocarditis. Nature, 611(7937), 818\u2013826.","journal-title":"Nature"},{"issue":"7","key":"9979_CR44","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41419-020-02778-2","volume":"11","author":"W Xia","year":"2020","unstructured":"Xia, W., Zou, C., Chen, H., et al. (2020). Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a\/Kruppel-like factor 4 signaling. Cell Death & Disease, 11(7), 575.","journal-title":"Cell Death & Disease"},{"issue":"2","key":"9979_CR45","doi-asserted-by":"publisher","first-page":"e001293","DOI":"10.1136\/jitc-2020-001293","volume":"8","author":"W Xia","year":"2020","unstructured":"Xia, W., Chen, H., Chen, D., et al. (2020). PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor-related cardiac dysfunction. Journal for Immunotherapy of Cancer, 8(2), e001293.","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"9979_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","volume":"149","author":"P Ma","year":"2024","unstructured":"Ma, P., Liu, J., Qin, J., et al. (2024). Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis. Circulation, 149(1), 48\u201366.","journal-title":"Circulation"},{"issue":"7","key":"9979_CR47","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41569-023-00986-9","volume":"21","author":"TG Gergely","year":"2024","unstructured":"Gergely, T. G., Drobni, Z. D., Kallikourdis, M., et al. (2024). Immune checkpoints in cardiac physiology and pathology: Therapeutic targets for heart failure. Nature Reviews Cardiology, 21(7), 443\u2013462.","journal-title":"Nature Reviews Cardiology"},{"issue":"6","key":"9979_CR48","doi-asserted-by":"publisher","first-page":"e002916","DOI":"10.1136\/jitc-2021-002916","volume":"9","author":"K Poels","year":"2021","unstructured":"Poels, K., Neppelenbroek, S. I. M., Kersten, M. J., et al. (2021). Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: An emerging clinical problem. Journal for Immunotherapy of Cancer, 9(6), e002916.","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"9","key":"9979_CR49","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/cells9091987","volume":"9","author":"K Poels","year":"2020","unstructured":"Poels, K., van Leent, M. M. T., Reiche, M. E., et al. (2020). Antibody-mediated inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice. Cells, 9(9), 1987.","journal-title":"Cells"},{"issue":"4","key":"9979_CR50","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","volume":"2","author":"K Poels","year":"2020","unstructured":"Poels, K., van Leent, M. M. T., Boutros, C., et al. (2020). Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis. JACC CardioOncology, 2(4), 599\u2013610.","journal-title":"JACC CardioOncology"},{"issue":"6","key":"9979_CR51","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jtha.2023.02.029","volume":"21","author":"A Falanga","year":"2023","unstructured":"Falanga, A., & Marchetti, M. (2023). Cancer-associated thrombosis: Enhanced awareness and pathophysiologic complexity. Journal of Thrombosis and Haemostasis, 21(6), 1397\u20131408.","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"11","key":"9979_CR52","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1055\/s-0043-1769609","volume":"123","author":"JD le Seve","year":"2023","unstructured":"le Seve, J. D., Guedon, A. F., Bordenave, S., et al. (2023). Risk factors of venous thromboembolic disease in cancer patients treated with immune checkpoint inhibitor. Thrombosis and Haemostasis, 123(11), 1049\u20131056.","journal-title":"Thrombosis and Haemostasis"},{"issue":"4","key":"9979_CR53","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/cells13040305","volume":"13","author":"C Freitas-Dias","year":"2024","unstructured":"Freitas-Dias, C., Goncalves, F., Martins, F., et al. (2024). Interaction between NSCLC Cells, CD8(+) T-cells and immune checkpoint inhibitors potentiates coagulation and promotes metabolic remodeling-new cues on CAT-VTE. Cells, 13(4), 305.","journal-title":"Cells"},{"issue":"8","key":"9979_CR54","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","volume":"34","author":"H Mir","year":"2018","unstructured":"Mir, H., Alhussein, M., Alrashidi, S., et al. (2018). Cardiac complications associated with checkpoint inhibition: A systematic review of the literature in an important emerging area. The Canadian Journal of Cardiology, 34(8), 1059\u20131068.","journal-title":"The Canadian Journal of Cardiology"},{"key":"9979_CR55","first-page":"e075859","volume":"385","author":"NL Palaskas","year":"2024","unstructured":"Palaskas, N. L., Ali, H. J., Koutroumpakis, E., et al. (2024). Cardiovascular toxicity of immune therapies for cancer. BMJ (Clinical Research Ed), 385, e075859.","journal-title":"BMJ (Clinical Research Ed)"},{"issue":"3","key":"9979_CR56","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson, J. A., Schneider, B. J., Brahmer, J., et al. (2020). NCCN guidelines insights: Management of immunotherapy-related toxicities, version 1.2020. Journal of the National Comprehensive Cancer Network, 18(3), 230\u2013241.","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"17","key":"9979_CR57","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer, J. R., Lacchetti, C., Schneider, B. J., et al. (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 36(17), 1714\u20131768.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"2","key":"9979_CR58","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano, G., Lenihan, D., Fradley, M., et al. (2020). Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 31(2), 171\u2013190.","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"6","key":"9979_CR59","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., et al. (2021). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for Immunotherapy of Cancer, 9(6), e002435.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"9979_CR60","doi-asserted-by":"publisher","first-page":"1394123","DOI":"10.3389\/fimmu.2024.1394123","volume":"15","author":"X Li","year":"2024","unstructured":"Li, X., & Li, D. (2024). Cardiovascular adverse events associated with immune checkpoint inhibitors: A meta-analysis. Frontiers in Immunology, 15, 1394123.","journal-title":"Frontiers in Immunology"},{"key":"9979_CR61","doi-asserted-by":"publisher","first-page":"101383","DOI":"10.1016\/j.tranon.2022.101383","volume":"19","author":"CB Xavier","year":"2022","unstructured":"Xavier, C. B., Lopes, C. D. H., Harada, G., et al. (2022). Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis. Translational Oncology, 19, 101383.","journal-title":"Translational Oncology"},{"key":"9979_CR62","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejca.2021.01.043","volume":"148","author":"E Agostinetto","year":"2021","unstructured":"Agostinetto, E., Eiger, D., Lambertini, M., et al. (2021). Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. European Journal of Cancer (Oxford, England: 1990), 148, 76\u201391.","journal-title":"European Journal of Cancer (Oxford, England: 1990)"},{"issue":"12","key":"9979_CR63","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S1470-2045(18)30622-3","volume":"19","author":"G Varricchi","year":"2018","unstructured":"Varricchi, G., Galdiero, M. R., Mercurio, V., et al. (2018). Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors. The Lancet Oncology, 19(12), 1545\u20131546.","journal-title":"The Lancet Oncology"},{"issue":"1","key":"9979_CR64","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/ijc.31301","volume":"143","author":"Y Wu","year":"2018","unstructured":"Wu, Y., Ju, Q., Jia, K., et al. (2018). Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). International Journal of Cancer, 143(1), 45\u201351.","journal-title":"International Journal of Cancer"},{"issue":"5","key":"9979_CR65","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/cvr\/cvz035","volume":"115","author":"WC Meijers","year":"2019","unstructured":"Meijers, W. C., & de Boer, R. A. (2019). Common risk factors for heart failure and cancer. Cardiovascular Research, 115(5), 844\u2013853.","journal-title":"Cardiovascular Research"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-09979-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-025-09979-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-09979-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T07:02:41Z","timestamp":1745391761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-025-09979-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["9979"],"URL":"https:\/\/doi.org\/10.1007\/s12012-025-09979-1","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"28 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}